What is the scope of U.S. Patent 9,662,340?
U.S. Patent 9,662,340 was granted on May 30, 2017, and assigned to Regeneron Pharmaceuticals, Inc. The patent primarily covers monoclonal antibody compositions and methods related to inhibiting or neutralizing PCSK9, a key regulator of LDL cholesterol. The patent emphasizes specific antibody structures, including amino acid sequences, and their use in lowering blood LDL levels.
Key Features:
- Claimed molecules: The patent claims monoclonal antibodies with specific variable region sequences targeting PCSK9.
- Functional characteristics: The antibodies can inhibit PCSK9 activity, leading to increased LDL receptor recycling.
- Methods of use: Methods for reducing LDL cholesterol levels in humans utilizing the claimed antibodies.
- Pharmacokinetic properties: Some claims specify antibodies with certain pharmacokinetic profiles, including half-life and affinity parameters.
Scope of Claims:
The claims are structured broadly to cover:
- Antibody compositions: Monoclonal antibodies with particular amino acid sequences, including modifications to enhance affinity or stability.
- Chimeric and humanized antibodies: Variations of antibody formats, including fully human or chimeric constructs.
- Methods: Therapeutic methods, including administering the antibodies to reduce LDL cholesterol or treat hypercholesterolemia.
- Variants: Pharmaceutical formulations and conjugates involving these antibodies.
The patent's claims extend to variants that maintain essential binding properties, such as specific epitope recognition or affinity thresholds, generally around nanomolar range.
What is the patent landscape surrounding U.S. Patent 9,662,340?
The patent landscape focuses on anti-PCSK9 monoclonal antibodies and their therapeutic use for hypercholesterolemia, with key competitors and related patents including:
Major Players and Patents:
- Regeneron’s Evolocumab (Repatha): Covered in patent families related to the same antibody sequences or similar epitope targeting, with patent filings as early as 2012.
- Amgen’s Alirocumab (Praluent): Patents related to different antibody sequences targeting PCSK9; their patent family includes filings from 2013.
- Other antibodies: Several companies, including Novartis, Sanofi, and Pfizer, hold patents on alternative PCSK9 inhibitors, often with different epitopes or formats.
Patent Scope and Overlap:
- U.S. patents for evolocumab and alirocumab typically cover distinct but overlapping antibody subclasses targeting PCSK9.
- The patent landscape includes filings covering nucleic acid sequences encoding these antibodies, methods of production, and pharmaceutical compositions.
- Patent challenges include arguments around antibody sequence similarity, functional claims, and the scope of variants.
Patent Term and Status:
- Many of these patents, including 9,662,340, have 20-year patent terms from their earliest priority date, often around 2012-2013, extending into the early 2030s.
- Some patents face challenges based on obviousness or prior art, especially regarding modified antibodies and specific epitope targeting.
Litigation and Licensing:
- The core patent rights for these antibodies are enforced through licensing agreements and patent infringement litigations. Regeneron has vigorously defended its patents, including 9,662,340.
- Competitors seek around these patents through design-around strategies involving alternative epitopes, formats (e.g., siRNA or gene editing), or combination therapies.
How do the claims relate to existing therapeutic antibodies?
Claims in 9,662,340 are specific to certain antibody sequences and binding properties, aligning with the antibody structure patents filed around 2012-2015. The patent emphasizes sequences with high affinity and specificity for PCSK9, consistent with marketed drugs.
The scope of claims generally avoids overlapping existing patents by focusing on unique amino acid sequences and modified antibody formats. This strategic framing limits infringement risks but leaves space for competitors to develop alternative antibodies targeting different epitopes or with different formats.
How does the patent landscape influence R&D and commercialization?
The robust patent scope around 9,662,340 grants Regeneron a competitive barrier against generic competition, extending exclusivity into the early 2030s. Patent families surrounding similar antibodies, including alirocumab, create overlapping exclusivity, fostering a patent thicket.
New entrants must navigate around this landscape by developing different epitopes, antibody formats, or combination therapies. Broadly, the patent landscape favors companies with comprehensive research programs and multiple patent families covering various aspects—from antibody sequences to manufacturing processes.
Key Takeaways
- U.S. Patent 9,662,340 covers specific monoclonal antibodies against PCSK9, including their sequences and methods of reduction of LDL cholesterol.
- The patent’s scope is broad, covering various antibody formats, compositions, and therapeutic methods.
- The landscape includes patents from Regeneron, Amgen, and other biotech firms, with overlapping claims on PCSK9 inhibitors and related antibodies.
- Patent barriers and litigation shape the competitive environment, influencing R&D strategies and commercialization pathways.
- The patent’s protection period extends into the early 2030s, maintaining advantage for the patent holder.
FAQs
1. Does U.S. Patent 9,662,340 cover all anti-PCSK9 antibodies?
No. It covers specific sequences and embodiments, but not all anti-PCSK9 antibodies. Variants with different sequences or binding epitopes may avoid infringement.
2. Is the patent valid in jurisdictions outside the U.S.?
Patents are jurisdiction-specific. The patent has counterparts in other regions, but protection depends on local patent laws and filings.
3. Can competitors develop different antibodies to bypass this patent?
Yes. Developing antibodies targeting different epitopes or formats (e.g., small molecules, siRNA) offers design-around strategies.
4. How does this patent impact biosimilar development?
It restricts biosimilar entry until the patent expires or is invalidated, necessitating legal clearance or licensing for biosimilar products.
5. What is the likelihood of patent challenges or invalidations?
Litigation and patent exam processes aim to challenge scope; however, existing legal defenses and prior art countermeasures often sustain patent validity.
References:
[1] USPTO. U.S. Patent 9,662,340.
[2] Regeneron Pharmaceuticals patent filings.
[3] Market data on PCSK9 inhibitors.
[4] Patent landscape reports on monoclonal antibodies.
